Welcome to our dedicated page for Applied Therapeutics news (Ticker: APLT), a resource for investors and traders seeking the latest updates and insights on Applied Therapeutics stock.
Applied Therapeutics Inc (APLT) has entered into an agreement to be acquired by Cycle Pharmaceuticals, marking a significant corporate transformation for this rare disease biotechnology company. This news page tracks developments related to Applied Therapeutics, including the pending acquisition, regulatory updates, and historical clinical development progress. Investors following this ticker should monitor announcements regarding the transaction completion and any material changes to the company's status.
As a clinical-stage biopharmaceutical company, Applied Therapeutics' news flow historically centered on clinical trial progress, regulatory communications, and corporate developments. The company focused on rare metabolic disorders and pediatric conditions, making FDA interactions and clinical data releases particularly significant events. Regulatory announcements such as Complete Response Letters or approval decisions represented pivotal moments affecting the company's trajectory.
The acquisition announcement by Cycle Pharmaceuticals represents the most material recent development for Applied Therapeutics shareholders. News coverage includes transaction details, shareholder communications, and updates on the acquisition timeline. Additional news categories relevant to Applied Therapeutics include leadership changes, financial results, clinical program updates, and regulatory filings. Understanding both the company's historical rare disease development focus and the current acquisition context provides essential perspective for tracking this stock.
Biotechnology news requires context about development stages, regulatory processes, and the binary nature of clinical and regulatory outcomes. For Applied Therapeutics, following both acquisition-related announcements and any ongoing clinical or regulatory developments helps investors understand the company's evolving status. This news resource provides comprehensive coverage of material developments affecting APLT shareholders.
Applied Therapeutics (Nasdaq: APLT) has been added to the Russell 3000® Index, effective after the U.S. market closed on June 28, 2024. This inclusion is part of the 2024 annual reconstitution of Russell indexes, which track the performance of the largest 3,000 U.S. stocks. This milestone highlights Applied Therapeutics' progress as a publicly traded company focused on developing novel drug candidates for diseases with high unmet medical needs.
CEO Shoshana Shendelman emphasized the significance of this addition, noting upcoming regulatory updates for their drug candidates, govorestat, for Classic Galactosemia and SORD Deficiency. The Russell 3000® Index is a key component of the global Russell indexes, used by investment managers and institutional investors to benchmark over $10 trillion in assets.
Applied Therapeutics, Inc. reported financial results for the first quarter of 2024, highlighting significant regulatory progress regarding the potential approval of govorestat for Classic Galactosemia in the US and EU. The Company also discussed a potential NDA submission for SORD Deficiency. Dale Hooks was appointed as Chief Commercial Officer, and full results from the Phase 3 ARISE-HF Study of AT-001 in Diabetic Cardiomyopathy were presented. Financially, the Company ended the quarter with $146.5 million in cash and cash equivalents, with a net loss of $83.9 million. The Company expects its cash to fund operations into 2026.
Applied Therapeutics, Inc. (Nasdaq: APLT) will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on May 14, 2024. The company is a clinical-stage biopharmaceutical developing drug candidates for unmet medical needs.
FAQ
What is the current stock price of Applied Therapeutics (APLT)?
What is the market cap of Applied Therapeutics (APLT)?
